Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors (Q37813152)

23 August 2017

1 reference

title

Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors (English)

1 reference

23 August 2017

1 reference

1

0 references

author name string

Emanuela Sant'antonio

2

1 reference

23 August 2017

Giuseppa Penna

3

1 reference

23 August 2017

Andrea Alonci

4

1 reference

23 August 2017

Arianna D'Angelo

5

1 reference

23 August 2017

Sabina Russo

6

1 reference

23 August 2017

Antonino Cannavò

7

1 reference

23 August 2017

Demetrio Gerace

8

1 reference

23 August 2017

Caterina Musolino

9

1 reference

23 August 2017

20 December 2010

1 reference

European Journal of Haematology

23 August 2017

1 reference

23 August 2017

86

1 reference

23 August 2017

2

1 reference

23 August 2017

93-110

1 reference

Review of 1027 patients with newly diagnosed multiple myeloma

23 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

A strategic framework for novel drug development in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Advances in biology of multiple myeloma: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

From the bench to the bedside: emerging new treatments in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Bone marrow microenvironment and the identification of new targets for myeloma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Heat shock protein 90 as a molecular target for cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Novel therapeutic targets for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Heat-shock proteins as regulators of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

HSP90 and the chaperoning of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Hyperthermia-associated carboplatin resistance: differential role of p53, HSF1 and Hsp70 in hepatoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Update on Hsp90 inhibitors in clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

A new puffing pattern induced by temperature shock and DNP in drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Discovery of the heat shock response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Heat shock response--pathophysiological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Role of the heat shock response and molecular chaperones in oncogenesis and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Hsp70 and Hsp90--a relay team for protein folding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Sequence and regulation of a gene encoding a human 89-kilodalton heat shock protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Inducible heat shock protein 70 expression as a potential predictive marker of metastasis in breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Differential expression of 70-kDa heat shock-protein in human oral tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Heat shock proteins and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Molecular chaperones in the cytosol: from nascent chain to folded protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Disassembly of transcriptional regulatory complexes by molecular chaperones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Heat shock proteins and their use as anticancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Disruption of HSP90 function reverts tumor necrosis factor-induced necrosis to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Oncogenic mutations reduce the stability of SRC kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Antiapoptotic function of Bcl-2 in mast cells is dependent on its association with heat shock protein 90beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Hsp90 isoforms: functions, expression and clinical importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

A Grp on the Hsp90 mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

The HSP90 family of genes in the human genome: insights into their divergence and evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Steroid receptor interactions with heat shock protein and immunophilin chaperones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Heat shock protein 90-antagonist destabilizes Bcr-Abl/HSP90 chaperone complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

The Hsp90 chaperone complex as a novel target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Structure, function, and mechanism of the Hsp90 molecular chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Independent ATPase activity of Hsp90 subunits creates a flexible assembly platform

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Structure of TPR domain-peptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Hsp90 and Cdc37 -- a chaperone cancer conspiracy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Hsp90 chaperone complexes are required for the activity and stability of yeast protein kinases Mik1, Wee1 and Swe1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Hsp90 inhibitors identified from a library of novobiocin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

21 January 2018

Hsp90: a drug target?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 kDa heat shock protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Heat shock protein 90 as a drug target: some like it hot.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Elevation of IL-6 in transgenic mice results in increased levels of the 90 kDa heat shock protein (hsp90) and the production of anti-hsp90 antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Interleukin 6 activates heat-shock protein 90 beta gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

The nuclear factor interleukin-6 (NF-IL6) and signal transducer and activator of transcription-3 (STAT-3) signalling pathways co-operate to mediate the activation of the hsp90beta gene by interleukin-6 but have opposite effects on its inducibility b

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

CCAAT/enhancer binding proteins and interferon signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Antimyeloma activity of heat shock protein-90 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Heat shock proteins as targets in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

17 AAG for HSP90 inhibition in cancer--from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino-17-demethoxygeldanamycin and actinomycin d.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Novel biologically based therapeutic strategies in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Hsp90 inhibition results in autophagy-mediated proteasome-independent degradation of IkappaB kinase (IKK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Targeting autophagic regulation of NFkappaB in HTLV-I transformed cells by geldanamycin: implications for therapeutic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Hsp90 as a capacitor for morphological evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Untangling the unfolded protein response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Inhibition of Hsp90: a multitarget approach to radiosensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Activation of natural killer cells by heat shock protein 70. 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Dual role of heat shock proteins as regulators of apoptosis and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Select forms of tumor cell apoptosis induce dendritic cell maturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Cellular protein is the source of cross-priming antigen in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

CD8+ T cell cross-priming via transfer of proteasome substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

To fold or not to fold: modulation and consequences of Hsp90 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Future novel single agent and combination therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Modulation of Hsf1 activity by novobiocin and geldanamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Intravascular delivery of particulate systems: does geometry really matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Shape effect of carbon nanovectors on angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

The effect of particle design on cellular internalization pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Intelligent biosynthetic nanobiomaterials for hyperthermic combination chemotherapy and thermal drug targeting of HSP90 inhibitor geldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Hsp90alpha recruited by Sp1 is important for transcription of 12(S)-lipoxygenase in A431 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

HSP90/70 chaperones are required for rapid nucleosome removal upon induction of the GAL genes of yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

The 90 kDa heat shock protein (hsp90) induces the condensation of the chromatin structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Trithorax requires Hsp90 for maintenance of active chromatin at sites of gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Targeting Hsp90: small-molecule inhibitors and their clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

In vivo stress preconditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

New insights into the mechanism of heat shock response activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Clinical and cellular pharmacology in relation to solid tumours of childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01558.X

10.1111/J.1600-0609.2010.01558.X

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference